{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:59:18Z","timestamp":1789570758793,"version":"build-2803163510"},"reference-count":285,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002661","name":"FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002910","name":"F\u00e9d\u00e9ration Wallonie-Bruxelles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002910","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003134","name":"FRIA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006401","name":"Fondation Charcot","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jconrel.2023.10.052","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:57:57Z","timestamp":1699466277000},"page":"435-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis"],"prefix":"10.1016","volume":"364","author":[{"given":"Ariane","family":"Mwema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio G.","family":"Muccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"des Rieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.10.052_bb0005","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0015","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"G. Multiple Sclerosis Therapy Consensus, Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"14","key":"10.1016\/j.jconrel.2023.10.052_bb0020","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"10130","key":"10.1016\/j.jconrel.2023.10.052_bb0025","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.724718","article-title":"Progress in the application of drugs for the treatment of multiple sclerosis","volume":"12","author":"Wei","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb0035","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb0045","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.052_bb0050","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/acn3.51401","article-title":"Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis","volume":"8","author":"Hart","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0055","first-page":"95","article-title":"Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1","volume":"11","author":"Rafiee Zadeh","year":"2019","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0060","first-page":"105","article-title":"Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2","volume":"11","author":"Rafiee Zadeh","year":"2019","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.808370","article-title":"Adverse drug reactions with drugs used in multiple sclerosis: an analysis from the italian pharmacovigilance database","volume":"13","author":"Barbieri","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5-6","key":"10.1016\/j.jconrel.2023.10.052_bb0070","first-page":"28","article-title":"It's time for combination therapies: in multiple sclerosis","volume":"14","author":"Avasarala","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: a renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"46","key":"10.1016\/j.jconrel.2023.10.052_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0085","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/1547691X.2016.1159264","article-title":"Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis","volume":"13","author":"Ghalamfarsa","year":"2016","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2016.12.010","article-title":"Multiple sclerosis: therapeutic applications of advancing drug delivery systems","volume":"86","author":"Dolati","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0095","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.addr.2021.05.006","article-title":"Extracellular vesicles for the treatment of central nervous system diseases","volume":"174","author":"Gratpain","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104068","article-title":"Update on treatment in multiple sclerosis","volume":"50","author":"Callegari","year":"2021","journal-title":"Presse Med."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0105","author":"N.M.S. Society"},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124312","article-title":"Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis","volume":"21","author":"Bross","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0120","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1007\/s00415-022-11063-5","article-title":"The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis","volume":"269","author":"Willison","year":"2022","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10127","key":"10.1016\/j.jconrel.2023.10.052_bb0130","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0135","author":"M. Clinic"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0140","article-title":"Therapeutic advances in multiple sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.578648","article-title":"Human commensal prevotella histicola ameliorates disease as effectively as interferon-beta in the experimental autoimmune encephalomyelitis","volume":"11","author":"Shahi","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0150","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1089\/jir.2014.0115","article-title":"Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon beta-1b","volume":"35","author":"Yu","year":"2015","journal-title":"J. Interf. Cytokine Res."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2023.10.052_bb0155","first-page":"S17","article-title":"Interferon-beta mechanisms of action in multiple sclerosis","volume":"74","author":"Dhib-Jalbut","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0160","author":"E.M. Agency"},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091578","article-title":"Glatiramer acetate immunomodulation: evidence of neuroprotection and cognitive preservation","volume":"11","author":"Kasindi","year":"2022","journal-title":"Cells"},{"issue":"15\u201316","key":"10.1016\/j.jconrel.2023.10.052_bb0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10354-022-00939-w","article-title":"An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis\u202f: immunotherapy with rituximab, ocrelizumab, and ofatumumab","volume":"172","author":"Ovchinnikov","year":"2022","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0175","series-title":"Natalizumab","author":"Babaesfahani","year":"2022"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4049\/jimmunol.2100176","article-title":"Therapeutic effect of anti-CD52 monoclonal antibody in multiple sclerosis and its animal models is mediated via t regulatory cells","volume":"209","author":"Kiapour","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.563645","article-title":"Effects of alemtuzumab on (auto)antigen-specific immune responses","volume":"11","author":"Hilger","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.jconrel.2023.10.052_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab","volume":"10","author":"Florou","year":"2020","journal-title":"Brain Sci"},{"issue":"15 Supplement","key":"10.1016\/j.jconrel.2023.10.052_bb0195","doi-asserted-by":"crossref","first-page":"P3.414","DOI":"10.1212\/WNL.90.15_supplement.P3.414","article-title":"Efficacy and safety of mitoxantrone use in aggressive multiple sclerosis (P3.414)","volume":"90","author":"Fabis-Pedrini","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0200","series-title":"EMA Summary of Product Characteristics","article-title":"Mitoxantrone","author":"E.M. Agency, Accord Healthcare Ltd","year":"2016"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0205","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0210","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-022-00927-z","article-title":"The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis","volume":"36","author":"Cohan","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010024","article-title":"Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action","volume":"8","author":"Behrangi","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/nmt-2021-0005","article-title":"Ozanimod for the treatment of relapsing forms of multiple sclerosis","volume":"11","author":"Kuczynski","year":"2021","journal-title":"Neurodegener Dis Manag"},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.052_bb0225","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0230","first-page":"61","article-title":"Ponesimod in the treatment of relapsing forms of multiple sclerosis: an update on the emerging clinical data","volume":"12","author":"Ruggieri","year":"2022","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730342","article-title":"Teriflunomide Treatment of multiple sclerosis selectively modulates CD8 memory T cells","volume":"12","author":"Tilly","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0240","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00109-019-01761-5","article-title":"Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis","volume":"97","author":"Yadav","year":"2019","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fneur.2018.00005","article-title":"Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis","volume":"9","author":"Mills","year":"2018","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/nmt-2020-0025","article-title":"Diroximel fumarate in the treatment of multiple sclerosis","volume":"10","author":"Jonasson","year":"2020","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/neurolint13020022","article-title":"Monomethyl fumarate (MMF, bafiertam) for the treatment of relapsing forms of multiple sclerosis (MS)","volume":"13","author":"Berger","year":"2021","journal-title":"Neurol. Int."},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123488","article-title":"Immunomodulatory effects associated with cladribine treatment","volume":"10","author":"Fissolo","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0270","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","article-title":"The clinical pharmacokinetics of cladribine","volume":"32","author":"Liliemark","year":"1997","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.052_bb0275","first-page":"426","article-title":"Reviewing the unmet needs of patients with multiple sclerosis","volume":"8","author":"Mehr","year":"2015","journal-title":"Am Health Drug Benef."},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb0280","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/1352458512438239","article-title":"Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review","volume":"18","author":"Balak","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0285","first-page":"CMT.S8661","article-title":"Pharmacotherapeuetic options for the treatment of multiple sclerosis, clinical medicine insights","volume":"4","author":"Palmer","year":"2012","journal-title":"Therapeutics"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","volume":"12","author":"Brancati","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0295","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential mechanisms of action related to the efficacy and safety of cladribine","volume":"30","author":"Baker","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104793","article-title":"Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology","volume":"156","author":"Jozefczuk","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0305","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/14740338.4.2.219","article-title":"Toxicity of the topoisomerase II inhibitors","volume":"4","author":"Seiter","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0310","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3324\/haematol.2011.041970","article-title":"Therapy-related acute promyelocytic leukemia","volume":"96","author":"Ravandi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103522","article-title":"Atypical antipsychotics in multiple sclerosis: a review of their in vivo immunomodulatory effects","volume":"58","author":"Stamoula","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.052_bb0320","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2008.06.031","article-title":"Central nervous system-directed effects of FTY720 (fingolimod)","volume":"274","author":"Miron","year":"2008","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0325","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","article-title":"The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis","volume":"58","author":"Hermann","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"10 Supplement","key":"10.1016\/j.jconrel.2023.10.052_bb0330","article-title":"Brain distribution of MS565, an imaging analogue of siponimod (BAF312), in non-human Primates (P1.168)","volume":"82","author":"Tavares","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8070227","article-title":"Sphingosine-1-phosphate: its pharmacological regulation and the treatment of multiple sclerosis: a review article","volume":"8","author":"Cohan","year":"2020","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.052_bb0340","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40263-022-00939-9","article-title":"Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments","volume":"36","author":"Faissner","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0345","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/530356","article-title":"Multiple sclerosis and the blood-central nervous system barrier","volume":"2013","author":"Palmer","year":"2013","journal-title":"Cardiovasc. Psychiatry Neurol."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.052_bb0350","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","article-title":"Remyelination in multiple sclerosis: from basic science to clinical translation","volume":"19","author":"Lubetzki","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0355","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/13543784.2020.1757647","article-title":"New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis","volume":"29","author":"Villoslada","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0360","article-title":"Oligodendrocyte development and regenerative therapeutics in multiple sclerosis","volume":"11","author":"Gacem","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103276","article-title":"Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence","volume":"65","author":"Manousi","year":"2021","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0370","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/WCO.0000000000001063","article-title":"New drugs for multiple sclerosis: new treatment algorithms","volume":"35","author":"Cree","year":"2022","journal-title":"Curr. Opin. Neurol."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.052_bb0375","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41573-022-00477-5","article-title":"Thinking outside the box: non-canonical targets in multiple sclerosis","volume":"21","author":"Bierhansl","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0380","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2015.03.042","article-title":"Animal models of multiple sclerosis","volume":"759","author":"Procaccini","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb0385","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jnr.24224","article-title":"Animal models of multiple sclerosis: focus on experimental autoimmune encephalomyelitis","volume":"96","author":"Bjelobaba","year":"2018","journal-title":"J. Neurosci. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb0390","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/acsptsci.9b00068","article-title":"Remyelination pharmacotherapy investigations highlight diverse mechanisms underlying multiple sclerosis progression","volume":"2","author":"Melchor","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.052_bb0395","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028977","article-title":"Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS)","volume":"8","author":"Glatigny","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0400","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0405","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbi.2019.05.029","article-title":"Astrocytes in multiple sclerosis and experimental autoimmune encephalomyelitis: Star-shaped cells illuminating the darkness of CNS autoimmunity","volume":"80","author":"Yi","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588021","article-title":"Microglia diversity in health and multiple sclerosis","volume":"11","author":"Zia","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0415","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00401-020-02217-8","article-title":"Extrinsic immune cell-derived, but not intrinsic oligodendroglial factors contribute to oligodendroglial differentiation block in multiple sclerosis","volume":"140","author":"Starost","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0420","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12974-020-01829-x","article-title":"Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL\/6 mice by inducing CD4(+) T cell apoptosis","volume":"17","author":"An","year":"2020","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb0425","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/cns.13111","article-title":"Nasal delivery of Fasudil-modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis","volume":"25","author":"Guo","year":"2019","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.052_bb0430","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/cns.12002","article-title":"Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect","volume":"18","author":"Hou","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0435","article-title":"Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105777","article-title":"Cordycepin (3'-deoxyadenosine) promotes remyelination via suppression of neuroinflammation in a cuprizone-induced mouse model of demyelination","volume":"75","author":"Jia","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114422","article-title":"Activation of FXR by ganoderic acid A promotes remyelination in multiple sclerosis via anti-inflammation and regeneration mechanism","volume":"185","author":"Jia","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0450","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.neuropharm.2012.06.025","article-title":"Epimedium flavonoids ameliorate experimental autoimmune encephalomyelitis in rats by modulating neuroinflammatory and neurotrophic responses","volume":"63","author":"Yin","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173523","article-title":"Icariin ameliorates the progression of experimental autoimmune encephalomyelitis by down-regulating the major inflammatory signal pathways in a mouse relapse-remission model of multiple sclerosis","volume":"885","author":"Cong","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020344","article-title":"Manipulating Macrophage\/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis","volume":"14","author":"Kuntzel","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105929","article-title":"Ethyl pyruvate enhances spontaneous remyelination by targeting microglia phagocytosis","volume":"77","author":"He","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0470","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41419-020-2287-5","article-title":"Correction: Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization","volume":"11","author":"Weng","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fimmu.2018.00050","article-title":"Cyclic AMP Pathway Suppress Autoimmune Neuroinflammation by Inhibiting Functions of Encephalitogenic CD4 T Cells and Enhancing M2 Macrophage Polarization at the Site of Inflammation","volume":"9","author":"Veremeyko","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0480","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.54","article-title":"Minocycline selectively inhibits M1 polarization of microglia","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Cell Death Dis."},{"issue":"1-2","key":"10.1016\/j.jconrel.2023.10.052_bb0485","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jneuroim.2004.08.011","article-title":"Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination","volume":"158","author":"Li","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0490","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1742-2094-7-46","article-title":"Resveratrol differentially modulates inflammatory responses of microglia and astrocytes","volume":"7","author":"Lu","year":"2010","journal-title":"J. Neuroinflammation"},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0495","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1007\/s12035-016-9891-5","article-title":"Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study","volume":"54","author":"Ghaiad","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"10","key":"10.1016\/j.jconrel.2023.10.052_bb0500","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0505","doi-asserted-by":"crossref","first-page":"144","DOI":"10.9758\/cpn.2013.11.3.144","article-title":"Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures","volume":"11","author":"Al-Amin","year":"2013","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062891","article-title":"The current challenges for drug discovery in CNS Remyelination","volume":"22","author":"Balestri","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7718","key":"10.1016\/j.jconrel.2023.10.052_bb0515","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41586-018-0360-3","article-title":"Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination","volume":"560","author":"Hubler","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0520","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbadis.2010.09.010","article-title":"Cells of the oligodendroglial lineage, myelination, and remyelination","volume":"1812","author":"Miron","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103539","article-title":"Remyelination trial failures: repercussions of ignoring neurorehabilitation and exercise in repair","volume":"58","author":"Ploughman","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0530","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41593-018-0120-6","article-title":"Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain","volume":"21","author":"Hill","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0535","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","article-title":"Metformin restores CNS remyelination capacity by rejuvenating aged stem cells","volume":"25","author":"Neumann","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.jconrel.2023.10.052_bb0540","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tics.2013.08.001","article-title":"Bridging animal and human models of exercise-induced brain plasticity","volume":"17","author":"Voss","year":"2013","journal-title":"Trends Cogn. Sci."},{"issue":"15","key":"10.1016\/j.jconrel.2023.10.052_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158418","article-title":"Targeting fibronectin to overcome remyelination failure in multiple sclerosis: the need for brain- and lesion-targeted drug delivery","volume":"23","author":"van Schaik","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0550","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/13524585211008760","article-title":"Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review","volume":"28","author":"Allanach","year":"2022","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0555","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1191\/1352458502ms768oa","article-title":"A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients","volume":"8","author":"Frank","year":"2002","journal-title":"Mult. Scler."},{"issue":"Pt B","key":"10.1016\/j.jconrel.2023.10.052_bb0560","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.expneurol.2016.02.023","article-title":"The role of growth factors as a therapeutic approach to demyelinating disease","volume":"283","author":"Huang","year":"2016","journal-title":"Exp. Neurol."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/nu11071528","article-title":"A review of various antioxidant compounds and their potential utility as complementary therapy in multiple sclerosis","volume":"11","author":"Miller","year":"2019","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07615","article-title":"N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis","volume":"7","author":"Shahrampour","year":"2021","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0575","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0306-3623(96)00474-0","article-title":"The pharmacology of the antioxidant lipoic acid","volume":"29","author":"Biewenga","year":"1997","journal-title":"Gen. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb0580","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11940-019-0566-1","article-title":"Lipoic acid and other antioxidants as therapies for multiple sclerosis","volume":"21","author":"Waslo","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0585","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/71555","article-title":"Glutamate excitotoxicity in a model of multiple sclerosis","volume":"6","author":"Pitt","year":"2000","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051663","article-title":"Strategies for neuroprotection in multiple sclerosis and the role of calcium","volume":"21","author":"Enders","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0595","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.conb.2019.03.006","article-title":"Mechanisms of injury-induced axon degeneration","volume":"57","author":"Ding","year":"2019","journal-title":"Curr. Opin. Neurobiol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108588","article-title":"Small molecule SARM1 inhibitors recapitulate the SARM1(-\/-) phenotype and allow recovery of a metastable pool of axons fated to degenerate","volume":"34","author":"Hughes","year":"2021","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0605","first-page":"252","article-title":"Drug delivery to the central nervous system: a review","volume":"6","author":"Misra","year":"2003","journal-title":"J. Pharm Pharm. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0610","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb0615","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.addr.2004.07.009","article-title":"Potential role of ABC transporters as a detoxification system at the blood-CSF barrier","volume":"56","author":"de Lange","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0620","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/09687688.2014.937468","article-title":"The blood-brain barrier: structure, function and therapeutic approaches to cross it","volume":"31","author":"Tajes","year":"2014","journal-title":"Mol. Membr. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0625","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barr. CNS"},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2023.10.052_bb0630","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood-brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0635","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2211068214561025","article-title":"TEER measurement techniques for in vitro barrier model systems","volume":"20","author":"Srinivasan","year":"2015","journal-title":"J. Lab Autom."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0640","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fnins.2020.00764","article-title":"Blood-brain barrier: more contributor to disruption of central nervous system homeostasis than victim in neurological disorders","volume":"14","author":"Xiao","year":"2020","journal-title":"Front. Neurosci."},{"issue":"16","key":"10.1016\/j.jconrel.2023.10.052_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168370","article-title":"Reviewing the significance of blood-brain barrier disruption in multiple sclerosis pathology and treatment","volume":"22","author":"Balasa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0650","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1208\/s12248-008-9009-8","article-title":"Prodrug approaches for CNS delivery","volume":"10","author":"Rautio","year":"2008","journal-title":"AAPS J."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0655","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s11095-022-03241-x","article-title":"Targeting transporters for drug delivery to the brain: can we do better?","volume":"39","author":"Puris","year":"2022","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb0660","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40259-017-0248-z","article-title":"Delivery of biologics across the blood-brain barrier with molecular trojan horse technology","volume":"31","author":"Pardridge","year":"2017","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0665","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","article-title":"Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein","volume":"14","author":"Boado","year":"2017","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0670","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/acs.molpharmaceut.7b00958","article-title":"Reduction in brain heparan sulfate with systemic administration of an igg trojan horse-sulfamidase fusion protein in the mucopolysaccharidosis Type IIIA Mouse","volume":"15","author":"Boado","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0675","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2020.602236","article-title":"Brain delivery of nanomedicines: trojan horse liposomes for plasmid DNA gene therapy of the brain","volume":"2","author":"Pardridge","year":"2020","journal-title":"Front. Med. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0680","doi-asserted-by":"crossref","first-page":"13334","DOI":"10.1038\/s41598-020-70290-w","article-title":"Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes","volume":"10","author":"Jiang","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0685","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007049806660","article-title":"Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications","volume":"20","author":"Rapoport","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0690","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1023\/B:HIJO.0000045969.52516.59","article-title":"Immunogold localization of tight junctional proteins in normal and osmotically-affected rat blood-brain barrier","volume":"35","author":"Dobrogowska","year":"2004","journal-title":"J. Mol. Histol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.10.052_bb0695","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0006-8993(94)90863-X","article-title":"Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors","volume":"659","author":"Nomura","year":"1994","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0700","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/sj.bjp.0705554","article-title":"Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries","volume":"140","author":"Erdlenbruch","year":"2003","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0705","first-page":"252","article-title":"Effects of histamine on brain capillaries. Fine structural and immunohistochemical studies after intracarotid infusion","volume":"47","author":"Dux","year":"1982","journal-title":"Exp. Brain Res."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0710","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ultrasmedbio.2004.04.010","article-title":"Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles","volume":"30","author":"Sheikov","year":"2004","journal-title":"Ultrasound Med. Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0715","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ultrasmedbio.2007.12.015","article-title":"Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium","volume":"34","author":"Sheikov","year":"2008","journal-title":"Ultrasound Med. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0720","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1038\/s41598-020-73312-9","article-title":"Consistent opening of the blood brain barrier using focused ultrasound with constant intravenous infusion of microbubble agent","volume":"10","author":"Lapin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0725","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.expneurol.2013.05.008","article-title":"Amyloid-beta plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound","volume":"248","author":"Jordao","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0730","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.665722","article-title":"Targeted blood brain barrier opening with focused ultrasound induces focal macrophage\/microglial activation in experimental autoimmune encephalomyelitis","volume":"15","author":"Schregel","year":"2021","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0735","article-title":"Endoscopic-assisted ommaya reservoir placement: technical note","volume":"9","author":"Lane","year":"2017","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0740","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2007.08.003","article-title":"Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model","volume":"123","author":"Kim","year":"2007","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.jconrel.2023.10.052_bb0745","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.biomaterials.2012.04.048","article-title":"Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model","volume":"33","author":"Masi","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0750","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3171\/2014.10.JNS14229","article-title":"Convection-enhanced delivery to the central nervous system","volume":"122","author":"Lonser","year":"2015","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cobme.2017.09.002","article-title":"Nanomaterials for convection-enhanced delivery of agents to treat brain tumors","volume":"4","author":"Seo","year":"2017","journal-title":"Curr Opin Biomed Eng"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0760","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-brain delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0765","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jddst.2017.09.022","article-title":"Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders","volume":"43","author":"Md","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0770","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018024697","article-title":"Updated progress of nanocarrier-based intranasal drug delivery systems for treatment of brain diseases","volume":"35","author":"Fan","year":"2018","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0775","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030629","article-title":"Evaluation of recent intranasal drug delivery systems to the central nervous system","volume":"14","author":"Crowe","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0780","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0785","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jneumeth.2018.03.006","article-title":"Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques","volume":"303","author":"Stenslik","year":"2018","journal-title":"J. Neurosci. Methods"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0790","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0795","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"Ganger","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0800","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0805","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0810","first-page":"600","article-title":"Administration of substances to laboratory animals: routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0815","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12883-017-0908-0","article-title":"Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study","volume":"17","author":"Santos-Morales","year":"2017","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0820","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11095-017-2280-6","article-title":"Numerical comparison of nasal aerosol administration systems for efficient nose-to-brain drug delivery","volume":"35","author":"Dong","year":"2017","journal-title":"Pharm. Res."},{"issue":"S9","key":"10.1016\/j.jconrel.2023.10.052_bb0825","doi-asserted-by":"crossref","DOI":"10.1186\/1753-6561-9-S9-O11","article-title":"Protein aerosol for intranasal nose to brain (N2B) delivery","volume":"9","author":"St\u00fctzle","year":"2015","journal-title":"BMC Proc."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0830","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb0835","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2011.0924","article-title":"Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump","volume":"25","author":"Djupesland","year":"2012","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0840","article-title":"Non-invasive strategies for nose-to-brain drug delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J. Clin. Trials"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0845","series-title":"Nasal drug Delivery Device","author":"Hoekman","year":"2017"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0850","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jddst.2016.05.003","article-title":"Formulation and device design to increase nose to brain drug delivery","volume":"35","author":"Warnken","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb0855","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal delivery of high molecular weight drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0860","article-title":"Modulation of olfactory area for effective transportation of actives in CNS disorders","volume":"68","author":"Jain","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0865","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2014.09.017","article-title":"Therapeutic applications of the cell-penetrating HIV-1 Tat peptide","volume":"20","author":"Rizzuti","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0870","doi-asserted-by":"crossref","first-page":"17641","DOI":"10.1038\/s41598-018-36210-9","article-title":"Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction","volume":"8","author":"Kamei","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb0875","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8020012","article-title":"Evaluation of P-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay","volume":"8","author":"Jouan","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118635","article-title":"Strategies to facilitate or block nose-to-brain drug delivery","volume":"570","author":"Martins","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0885","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10010034","article-title":"Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting","volume":"10","author":"Sonvico","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0890","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijpharm.2019.05.032","article-title":"Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges","volume":"565","author":"Chatterjee","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.052_bb0895","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081929","article-title":"Intranasal Delivery of Nanoformulations: a potential way of treatment for neurological disorders","volume":"25","author":"Islam","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0900","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0973-8398.45032","article-title":"Bioavailability of intranasal drug delivery system","volume":"2","author":"Bhise","year":"2008","journal-title":"Asian J. Pharmaceut."},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb0905","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/jphp.12749","article-title":"Modulating nasal mucosal permeation using metabolic saturation and enzyme inhibition techniques","volume":"69","author":"Dhamankar","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0910","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis","volume":"18","author":"Devonshire","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0915","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7812\/TPP\/18-033","article-title":"The unmet challenge of medication nonadherence","volume":"22","author":"Kleinsinger","year":"2018","journal-title":"Perm J"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0920","doi-asserted-by":"crossref","first-page":"12447","DOI":"10.1038\/s41598-022-16790-3","article-title":"Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study","volume":"12","author":"Giedraitiene","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb0925","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10060338","article-title":"Promising nanotechnology approaches in treatment of autoimmune diseases of central nervous system","volume":"10","author":"Chountoulesi","year":"2020","journal-title":"Brain Sci"},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb0930","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1111\/ejn.15478","article-title":"Nanosystems and exosomes as future approaches in treating multiple sclerosis","volume":"54","author":"Sidoryk-Wegrzynowicz","year":"2021","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0935","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030101","article-title":"Neuronanomedicine: an up-to-date overview","volume":"11","author":"Teleanu","year":"2019","journal-title":"Pharmaceutics"},{"issue":"15","key":"10.1016\/j.jconrel.2023.10.052_bb0940","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1039\/C9TB00170K","article-title":"Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0945","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jconrel.2020.03.042","article-title":"Lipid nanocapsules to enhance drug bioavailability to the central nervous system","volume":"322","author":"Moura","year":"2020","journal-title":"J. Control. Release"},{"issue":"17","key":"10.1016\/j.jconrel.2023.10.052_bb0950","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0955","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1039\/C8RA08972H","article-title":"Microfluidic assisted synthesis of PLGA drug delivery systems","volume":"9","author":"Rezvantalab","year":"2019","journal-title":"RSC Adv."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18318","article-title":"Microfluidics-based PLGA nanoparticles of ratiometric multidrug: from encapsulation and release rates to cytotoxicity in human lens epithelial cells","volume":"9","author":"Guo","year":"2023","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0965","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040500","article-title":"PLGA nanoparticle-based formulations to cross the blood-brain barrier for drug delivery: from R&D to cGMP","volume":"13","author":"Zhi","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1-2","key":"10.1016\/j.jconrel.2023.10.052_bb0970","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ijpharm.2017.06.052","article-title":"Polymeric nanoparticles: promising platform for drug delivery","volume":"528","author":"El-Say","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040571","article-title":"Insights into exosome transport through the blood-brain barrier and the potential therapeutical applications in Brain diseases","volume":"16","author":"Abdelsalam","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2023.10.052_bb0980","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fbioe.2020.00437","article-title":"Strategies to obtain encapsulation and controlled release of small hydrophilic molecules","volume":"8","author":"Li","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb0985","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/tnsci-2022-0258","article-title":"Nanotechnology-based drug delivery for the treatment of CNS disorders","volume":"13","author":"Mittal","year":"2022","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.jconrel.2023.10.052_bb0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120640","article-title":"Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery","volume":"602","author":"Urimi","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb0995","first-page":"897","article-title":"Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance","volume":"51","author":"Coon","year":"1991","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1000","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2006.02.014","article-title":"Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition","volume":"112","author":"Lamprecht","year":"2006","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb1005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejps.2010.04.015","article-title":"Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells","volume":"40","author":"Roger","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb1010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nnm-2018-0120","article-title":"Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities","volume":"14","author":"Farjadian","year":"2019","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.colsurfb.2017.10.062","article-title":"Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation","volume":"161","author":"Graverini","year":"2018","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb1020","article-title":"Nanostructured lipid carriers to mediate brain delivery of temazepam: design and in vivo study","volume":"12","author":"E.E. N, M.O. M, A.M. H, A.A.-T. H","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2020.02.020","article-title":"Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting","volume":"321","author":"Agrawal","year":"2020","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jocit.2017.12.001","article-title":"A review on nanotechnology based innovations in diagnosis and treatment of multiple sclerosis","volume":"4","author":"Ojha","year":"2018","journal-title":"J. Cell. Immunother."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1035","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/abddf4","article-title":"Recent advances in development of nanomedicines for multiple sclerosis diagnosis","volume":"16","author":"Zhang","year":"2021","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biomaterials.2015.03.044","article-title":"Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)","volume":"56","author":"Rittchen","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1045","article-title":"Multiple Sclerosis: LIFNano-CD4 for trojan horse delivery of the neuro-protective biologic \"lif\" into the brain: preclinical proof of concept","volume":"3","author":"de la Flor","year":"2021","journal-title":"Front. Med. Technol."},{"issue":"27","key":"10.1016\/j.jconrel.2023.10.052_bb1050","doi-asserted-by":"crossref","first-page":"15893","DOI":"10.1039\/C9RA09928J","article-title":"Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles","volume":"10","author":"Fodor-Kardos","year":"2020","journal-title":"RSC Adv."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb1055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2012.06.022","article-title":"Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation","volume":"164","author":"Gaillard","year":"2012","journal-title":"J. Control. Release"},{"issue":"Pt 8","key":"10.1016\/j.jconrel.2023.10.052_bb1060","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/brain\/awg176","article-title":"Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis","volume":"126","author":"Schmidt","year":"2003","journal-title":"Brain"},{"issue":"1-2","key":"10.1016\/j.jconrel.2023.10.052_bb1065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jneuroim.2014.06.025","article-title":"Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis","volume":"274","author":"Lee","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.jconrel.2023.10.052_bb1070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130442","article-title":"Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases","volume":"10","author":"Turjeman","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb1075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jbiotec.2011.06.037","article-title":"Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide","volume":"156","author":"Re","year":"2011","journal-title":"J. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb1080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.nano.2011.05.004","article-title":"Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model","volume":"7","author":"Re","year":"2011","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010038","article-title":"ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood-brain barrier","volume":"13","author":"Topal","year":"2020","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb1090","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/10837450.2016.1226901","article-title":"Solid lipid nanoparticles surface modified with anti-Contactin-2 or anti-Neurofascin for brain-targeted delivery of medicines","volume":"22","author":"Gandomi","year":"2017","journal-title":"Pharm. Dev. Technol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1095","doi-asserted-by":"crossref","first-page":"225","DOI":"10.15171\/apb.2018.027","article-title":"Preparation and statistical modeling of solid lipid nanoparticles of dimethyl fumarate for better management of multiple sclerosis","volume":"8","author":"Ojha","year":"2018","journal-title":"Adv Pharm Bull"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1208\/s12249-019-1296-0","article-title":"oral delivery of methylthioadenosine to the brain employing solid lipid nanoparticles: pharmacokinetic, behavioral, and histopathological evidences","volume":"20","author":"Kumar","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jddst.2016.06.012","article-title":"Brain delivery of baclofen as a hydrophilic drug by nanolipid carriers: Characteristics and pharmacokinetics evaluation","volume":"37","author":"Ghasemian","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"4","key":"10.1016\/j.jconrel.2023.10.052_bb1110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/acschemneuro.6b00428","article-title":"Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies","volume":"8","author":"Kumar","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb1115","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/acschemneuro.7b00519","article-title":"Preclinical explorative assessment of dimethyl fumarate-based biocompatible nanolipoidal carriers for the management of multiple sclerosis","volume":"9","author":"Kumar","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb1120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","article-title":"Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies","volume":"45","author":"Gadhave","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb1125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202590","article-title":"Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis","volume":"13","author":"Laso-Garcia","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb1130","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1021\/acsnano.9b01004","article-title":"Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders","volume":"13","author":"Riazifar","year":"2019","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb1135","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121497","article-title":"Placental mesenchymal stem cell-derived extracellular vesicles promote myelin regeneration in an animal model of multiple sclerosis","volume":"8","author":"Clark","year":"2019","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.052_bb1140","doi-asserted-by":"crossref","first-page":"8779","DOI":"10.1002\/jcp.29721","article-title":"Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis","volume":"235","author":"Jafarinia","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"1-2","key":"10.1016\/j.jconrel.2023.10.052_bb1145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2013.10.014","article-title":"IFNgamma-stimulated dendritic cell exosomes as a potential therapeutic for remyelination","volume":"266","author":"Pusic","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb1150","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41598-021-81039-4","article-title":"Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation","volume":"11","author":"Giunti","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1155","first-page":"373","article-title":"Targeting central nervous system extracellular vesicles enhanced triiodothyronine remyelination effect on experimental autoimmune encephalomyelitis","volume":"9","author":"Xiao","year":"2022","journal-title":"Bioact. Mater."},{"issue":"568","key":"10.1016\/j.jconrel.2023.10.052_bb1160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba0599","article-title":"Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice","volume":"12","author":"Casella","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113895","article-title":"Exosomes derived from bone marrow mesenchymal stromal cells promote remyelination and reduce neuroinflammation in the demyelinating central nervous system","volume":"347","author":"Zhang","year":"2022","journal-title":"Exp. Neurol."},{"issue":"19","key":"10.1016\/j.jconrel.2023.10.052_bb1170","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1039\/D2BM00518B","article-title":"High-efficiency brain-targeted intranasal delivery of BDNF mediated by engineered exosomes to promote remyelination","volume":"10","author":"Zhai","year":"2022","journal-title":"Biomater Sci"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jconrel.2022.12.026","article-title":"Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia","volume":"353","author":"Zheng","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2022.01.051","article-title":"A targeted extracellular vesicles loaded with montelukast in the treatment of demyelinating diseases","volume":"594","author":"Xiao","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2023.10.052_bb1185","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1039\/D1NR05517H","article-title":"Engineered extracellular vesicles encapsulated Bryostatin-1 as therapy for neuroinflammation","volume":"14","author":"Wu","year":"2022","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1190","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020186","article-title":"MiR-219a-5p enriched extracellular vesicles induce OPC differentiation and EAE improvement more efficiently than liposomes and polymeric nanoparticles","volume":"12","author":"Osorio-Querejeta","year":"2020","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb1195","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.ymthe.2018.06.024","article-title":"Extracellular vesicles containing IL-4 modulate neuroinflammation in a mouse model of multiple Sclerosis","volume":"26","author":"Casella","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1200","article-title":"Chitosan-alginate core-shell-corona shaped nanoparticles of dimethyl fumarate in orodispersible film to improve bioavailability in treatment of multiple sclerosis: preparation, characterization and biodistribution in rats","volume":"64","author":"Sinha","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jconrel.2016.12.003","article-title":"Targeted delivery of glucocorticoids to macrophages in a mouse model of multiple sclerosis using inorganic-organic hybrid nanoparticles","volume":"245","author":"Montes-Cobos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1210","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jconrel.2016.06.013","article-title":"Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques","volume":"235","author":"Beyer","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb1215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010204","article-title":"Exploiting PLGA-based biocompatible nanoparticles for next-generation tolerogenic vaccines against autoimmune disease","volume":"20","author":"Cappellano","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640935","article-title":"Antigen-specific immune tolerance in multiple sclerosis-promising approaches and how to bring them to patients","volume":"12","author":"Lutterotti","year":"2021","journal-title":"Front. Immunol."},{"issue":"43","key":"10.1016\/j.jconrel.2023.10.052_bb1225","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1016\/j.vaccine.2014.08.016","article-title":"Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis","volume":"32","author":"Cappellano","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1230","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biomaterials.2017.07.029","article-title":"An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis","volume":"143","author":"Cho","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1240","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.2147\/IJN.S164500","article-title":"Direct modulation of myelin-autoreactive CD4(+) and CD8(+) T cells in EAE mice by a tolerogenic nanoparticle co-carrying myelin peptide-loaded major histocompatibility complexes, CD47 and multiple regulatory molecules","volume":"13","author":"Pei","year":"2018","journal-title":"Int. J. Nanomedicine"},{"issue":"12","key":"10.1016\/j.jconrel.2023.10.052_bb1245","doi-asserted-by":"crossref","DOI":"10.3390\/polym12123063","article-title":"Poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles loaded with proteolipid protein (PLP)-exploring a new administration route","volume":"12","author":"Lima","year":"2020","journal-title":"Polymers (Basel)"},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb1250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.34172\/apb.2021.058","article-title":"Prophylactic and therapeutic effects of MOG-conjugated PLGA nanoparticles in C57Bl\/6 mouse model of multiple sclerosis","volume":"11","author":"Gholamzad","year":"2021","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1255","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2021.01.013","article-title":"PEGylation enables subcutaneously administered nanoparticles to induce antigen-specific immune tolerance","volume":"331","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb1260","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1096\/fj.12-213975","article-title":"Liposome-encapsulated peptides protect against experimental allergic encephalitis","volume":"27","author":"Belogurov","year":"2013","journal-title":"FASEB J."},{"issue":"50","key":"10.1016\/j.jconrel.2023.10.052_bb1265","doi-asserted-by":"crossref","first-page":"32017","DOI":"10.1073\/pnas.2016451117","article-title":"Tolerogenic nanoparticles suppress central nervous system inflammation","volume":"117","author":"Kenison","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.jconrel.2023.10.052_bb1270","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2217\/nnm-2016-0410","article-title":"Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis","volume":"12","author":"Pujol-Autonell","year":"2017","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1275","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2021.05.027","article-title":"New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect","volume":"335","author":"Shimizu","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1280","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/IJN.S214349","article-title":"Development of nanosome-encapsulated honokiol for intravenous therapy against experimental autoimmune encephalomyelitis","volume":"15","author":"Hsiao","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1285","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.intimp.2018.12.001","article-title":"Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia","volume":"67","author":"Li","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"1-2","key":"10.1016\/j.jconrel.2023.10.052_bb1290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2004.02.011","article-title":"Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis","volume":"151","author":"Ross","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1295","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jconrel.2020.11.019","article-title":"Intranasal delivery of interferon-beta-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: A promising simple, effective, non-invasive, and low-cost therapy","volume":"331","author":"Gonzalez","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1300","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103518","article-title":"Intranasal administration of fingolimod (FTY720) attenuates demyelination area in lysolecithin-induced demyelination model of rat optic chiasm","volume":"59","author":"Ghasemi-Kasman","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1305","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnen\/nlz128","article-title":"Intranasal methylprednisolone effectively reduces neuroinflammation in mice with experimental autoimmune encephalitis","volume":"79","author":"Rassy","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1310","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0165-5728(97)00264-6","article-title":"Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats","volume":"84","author":"Xiao","year":"1998","journal-title":"J. Neuroimmunol."},{"issue":"43","key":"10.1016\/j.jconrel.2023.10.052_bb1315","doi-asserted-by":"crossref","first-page":"17558","DOI":"10.1073\/pnas.1314017110","article-title":"Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6","volume":"110","author":"Alhouayek","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1320","first-page":"102633","article-title":"Lipid nanocapsules for the nose-to-brain delivery of the anti-inflammatory bioactive lipid PGD(2)-G","author":"Mwema","year":"2022","journal-title":"Nanomedicine"},{"issue":"1-2","key":"10.1016\/j.jconrel.2023.10.052_bb1325","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0165-5728(97)00133-1","article-title":"Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA","volume":"80","author":"Bai","year":"1997","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.10.052_bb1330","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1365-2567.1998.00526.x","article-title":"Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats","volume":"94","author":"Li","year":"1998","journal-title":"Immunology"},{"issue":"1-2","key":"10.1016\/j.jconrel.2023.10.052_bb1335","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2010.04.014","article-title":"Antigen-specific therapy of EAE via intranasal delivery of filamentous phage displaying a myelin immunodominant epitope","volume":"225","author":"Rakover","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb1340","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425247.2011.566267","article-title":"Intranasal delivery of stem cells to the brain","volume":"8","author":"Jiang","year":"2011","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1345","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3389\/fneur.2020.00638","article-title":"Particles containing cells as a strategy to promote remyelination in patients with multiple sclerosis","volume":"11","author":"Matias-Guiu","year":"2020","journal-title":"Front. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2023.10.052_bb1350","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.3727\/096368914X684970","article-title":"Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer\u2019s and Parkinson\u2019s disease","volume":"23","author":"Danielyan","year":"2014","journal-title":"Cell Transplant."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.expneurol.2015.03.011","article-title":"Intranasal delivery of hypoxia-preconditioned bone marrow-derived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice","volume":"272","author":"Sun","year":"2015","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1360","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cbin.11250","article-title":"Intranasal delivery of SDF-1alpha-preconditioned bone marrow mesenchymal cells improves remyelination in the cuprizone-induced mouse model of multiple sclerosis","volume":"44","author":"Beigi Boroujeni","year":"2020","journal-title":"Cell Biol. Int."},{"issue":"19","key":"10.1016\/j.jconrel.2023.10.052_bb1365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910738","article-title":"Intranasal administration of undifferentiated oligodendrocyte lineage cells as a potential approach to deliver oligodendrocyte precursor cells into brain","volume":"22","author":"Gomez-Pinedo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2023.10.052_bb1370","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s12640-022-00556-w","article-title":"Glial response to intranasal mesenchymal stem cells in intermittent cuprizone model of demyelination","volume":"40","author":"Zarini","year":"2022","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.jconrel.2023.10.052_bb1375","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1380","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107207","article-title":"Intranasal administration of small extracellular vesicles derived from mesenchymal stem cells ameliorated the experimental autoimmune encephalomyelitis","volume":"90","author":"Fathollahi","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2023.10.052_bb1385","article-title":"Advances and opportunities in nanoparticle drug delivery for central nervous system disorders: a review of current advances","volume":"15","author":"Ekhator","year":"2023","journal-title":"Cureus"},{"issue":"6079","key":"10.1016\/j.jconrel.2023.10.052_bb1390","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1126\/science.1205441","article-title":"Science and regulation. FDA's approach to regulation of products of nanotechnology","volume":"336","author":"Hamburg","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1395","series-title":"B. R., FDA and Nanotech: Baby Steps Lead to Regulatory Uncertainty","year":"2013"},{"key":"10.1016\/j.jconrel.2023.10.052_bb1400","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2021.12.009","article-title":"Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies","volume":"341","author":"Goel","year":"2022","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb1405","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091870","article-title":"Nose-to-brain delivery of therapeutic peptides as nasal aerosols","volume":"14","author":"Alabsi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2023.10.052_bb1410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40263-020-00781-x","article-title":"Intranasal Insulin for Alzheimer's Disease","volume":"35","author":"Hallschmid","year":"2021","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2023.10.052_bb1415","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00405-019-05717-w","article-title":"Measurement of mucociliary clearance in the patients with multiple sclerosis","volume":"277","author":"Sahin","year":"2020","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"21","key":"10.1016\/j.jconrel.2023.10.052_bb1420","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111654","article-title":"Nanoparticles for targeted brain drug delivery: what do we know?","volume":"22","author":"Pinheiro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2023.10.052_bb1425","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40265-021-01526-w","article-title":"Failed, interrupted, or inconclusive trials on neuroprotective and neuroregenerative treatment strategies in multiple sclerosis: update 2015-2020","volume":"81","author":"Huntemann","year":"2021","journal-title":"Drugs"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:53:26Z","timestamp":1759164806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923007137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":285,"alternative-id":["S0168365923007137"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.052","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}